Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,095 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Control Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of MGD010 in Healthy Subjects

NCT02376036
View directory record Official record
Conditions
Healthy Subjects
Interventions
MGD010, Placebo, Hepatitis A vaccine
Drug · Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine

NCT01545349
View directory record Official record
Conditions
Healthy, Influenza
Interventions
Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo, Live attenuated influenza vaccine
Biological
Lead sponsor
Patricia L. Hibberd
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 10, 2026, 11:30 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Bronchoscopy Study for Severe Asthma

NCT01745809
View directory record Official record
Conditions
Severe Persistent Asthma
Interventions
Bronchoscopy
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

NCT01696604
View directory record Official record
Conditions
Cachexia
Interventions
GSK2849466, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion

NCT02247765
View directory record Official record
Conditions
Healthy, Hypoxia
Interventions
Arterial line, Motion
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

NCT01100021
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tamsulosin and avanafil, Doxazosin and avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Sep 10, 2026, 11:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Computer Interface Control of a Robotic Device

NCT02069938
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 10, 2026, 11:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SPECT/CT Imaging of Skeletal Muscle Perfusion

NCT02791204
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetes Mellitus
Interventions
SPECT/CT imaging following revascularization procedures, SPECT/CT imaging
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

NCT01209104
View directory record Official record
Conditions
Nutritional Status
Interventions
GSK1325756
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 10, 2026, 11:30 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

NCT01164904
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Amg 181
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Glendale, California • Danbury, Connecticut • Plymouth, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine, control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
5,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

NCT03432884
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A TQTc Study for Omaveloxolone

NCT05927649
View directory record Official record
Conditions
Health Adult Subjects
Interventions
Omaveloxolone, Moxifloxacin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 2 Interventional

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

NCT00169559
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GW590735, fenofibrate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2012 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

NCT05304910
View directory record Official record
Conditions
Migraine
Interventions
Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate BMS-830216 in Healthy Subjects

NCT00878020
View directory record Official record
Conditions
Obesity
Interventions
BMS-830216, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

NCT01334242
View directory record Official record
Conditions
Healthy
Interventions
Schedule A, Schedule B, Schedule C, Schedule D, Schedule E
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects

NCT00823940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1362885, Glucagon, Glucagon + GSK1362885
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

NCT01224262
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
Biological
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

NCT04588727
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

NCT02974374
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
PF-06835919, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 10, 2026, 11:30 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

NCT01916850
View directory record Official record
Conditions
Healthy
Interventions
LX4211 400 mg, LX4211 800 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 10, 2026, 11:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT05116826
View directory record Official record
Conditions
Moderate Hepatic Impairment, Severe Hepatic Impairment, Liver Diseases
Interventions
Nitazoxanide
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 10, 2026, 11:30 PM EDT